-
1
Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
Published 2018“…American Society of Hematology…”
Conference item -
2
Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb...
Published 2016“…American Society of Hematology…”
Conference item -
3
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Published 2015“…American Society of Hematology…”
Journal article -
4
Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Published 2018“…American Society of Hematology…”
Conference item -
5
Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia
Published 2017“…American Society of Hematology…”
Conference item -
6
Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations
Published 2018“…American Society of Hematology…”
Journal article -
7
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
Published 2019“…American Society of Hematology…”
Journal article -
8
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
Published 2017“…American Society of Hematology…”
Journal article